SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Pacira BioSciences, Inc. – ‘10-K’ for 12/31/12 – ‘EX-32.1’

On:  Thursday, 3/7/13, at 2:56pm ET   ·   For:  12/31/12   ·   Accession #:  1047469-13-2336   ·   File #:  1-35060

Previous ‘10-K’:  ‘10-K’ on 3/27/12 for 12/31/11   ·   Next:  ‘10-K’ on 2/25/14 for 12/31/13   ·   Latest:  ‘10-K’ on 2/29/24 for 12/31/23   ·   2 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/07/13  Pacira BioSciences, Inc.          10-K       12/31/12   87:9M                                     Toppan Merrill-FA

Annual Report   —   Form 10-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML    979K 
 2: EX-10.47    Material Contract                                   HTML    318K 
 3: EX-10.48    Material Contract                                   HTML    163K 
 4: EX-21.1     Subsidiaries List                                   HTML     20K 
 5: EX-23.1     Consent of Experts or Counsel                       HTML     25K 
 6: EX-31.1     Certification -- §302 - SOA'02                      HTML     28K 
 7: EX-31.2     Certification -- §302 - SOA'02                      HTML     28K 
 8: EX-32.1     Certification -- §906 - SOA'02                      HTML     24K 
 9: EX-32.2     Certification -- §906 - SOA'02                      HTML     24K 
59: R1          Document and Entity Information                     HTML     51K 
45: R2          Consolidated Balance Sheets                         HTML    144K 
57: R3          Consolidated Balance Sheets (Parenthetical)         HTML     49K 
61: R4          Consolidated Statements of Operations               HTML     90K 
80: R5          Consolidated Statements of Comprehensive Loss       HTML     48K 
48: R6          Consolidated Statements of Stockholders' Equity     HTML    135K 
                (Deficit)                                                        
56: R7          Consolidated Statements of Cash Flows               HTML    180K 
41: R8          Business                                            HTML     33K 
31: R9          Summary of Significant Accounting Policies          HTML     67K 
81: R10         Recent Accounting Pronouncements                    HTML     26K 
63: R11         Financial Instruments                               HTML     54K 
62: R12         Inventories                                         HTML     32K 
68: R13         Fixed Assets                                        HTML     38K 
69: R14         Goodwill and Intangible Assets                      HTML     55K 
66: R15         Accrued Expenses                                    HTML     31K 
70: R16         Debt                                                HTML     51K 
58: R17         Stockholders' Equity                                HTML     48K 
60: R18         Stock Plans                                         HTML     73K 
65: R19         Earnings Per Share                                  HTML     43K 
87: R20         Cost of Revenues                                    HTML     31K 
76: R21         Income Taxes                                        HTML     59K 
52: R22         Other Employee Benefits                             HTML     25K 
64: R23         Commercial Partners and Other Agreements            HTML     35K 
54: R24         Related Party Transactions                          HTML     35K 
23: R25         Commitments and Contingencies                       HTML     42K 
77: R26         Subsequent Events                                   HTML     26K 
84: R27         Summary of Significant Accounting Policies          HTML    145K 
                (Policies)                                                       
36: R28         Summary of Significant Accounting Policies          HTML     40K 
                (Tables)                                                         
35: R29         Financial Instruments (Tables)                      HTML     53K 
39: R30         Inventories (Tables)                                HTML     29K 
40: R31         Fixed Assets (Tables)                               HTML     33K 
42: R32         Goodwill and Intangible Assets (Tables)             HTML     52K 
21: R33         Accrued Expenses (Tables)                           HTML     30K 
74: R34         Debt (Tables)                                       HTML     35K 
50: R35         Stockholders' Equity (Tables)                       HTML     37K 
53: R36         Stock Plans (Tables)                                HTML     77K 
26: R37         Earnings Per Share (Tables)                         HTML     43K 
86: R38         Cost of Revenues (Tables)                           HTML     30K 
16: R39         Income Taxes (Tables)                               HTML     54K 
43: R40         Commitments and Contingencies (Tables)              HTML     29K 
79: R41         Summary of Significant Accounting Policies          HTML     29K 
                (Details)                                                        
25: R42         Summary of Significant Accounting Policies          HTML     43K 
                (Details 2)                                                      
34: R43         Summary of Significant Accounting Policies          HTML     31K 
                (Details 3)                                                      
38: R44         Financial Instruments (Details)                     HTML     26K 
46: R45         Financial Instruments (Details 2)                   HTML     47K 
20: R46         Financial Instruments (Details 3)                   HTML     31K 
30: R47         Inventories (Details)                               HTML     42K 
18: R48         Fixed Assets (Details)                              HTML     52K 
78: R49         Goodwill and Intangible Assets (Details)            HTML     44K 
24: R50         Goodwill and Intangible Assets (Details 2)          HTML     59K 
75: R51         Accrued Expenses (Details)                          HTML     36K 
27: R52         Debt (Details)                                      HTML    169K 
44: R53         Stockholders' Equity (Details)                      HTML     61K 
17: R54         Stockholders' Equity (Details 2)                    HTML     53K 
19: R55         Stock Plans (Details)                               HTML     37K 
37: R56         Stock Plans (Details 2)                             HTML     30K 
22: R57         Stock Plans (Details 3)                             HTML    117K 
82: R58         Earnings Per Share (Details)                        HTML     42K 
49: R59         Earnings Per Share (Details 2)                      HTML     33K 
67: R60         Cost of Revenues (Details)                          HTML     30K 
29: R61         Income Taxes (Details)                              HTML     79K 
32: R62         Income Taxes (Details 2)                            HTML     45K 
73: R63         Other Employee Benefits (Details)                   HTML     25K 
71: R64         Commercial Partners and Other Agreements (Details)  HTML     29K 
51: R65         Related Party Transactions (Details)                HTML     60K 
72: R66         Commitments and Contingencies (Details)             HTML     63K 
28: R67         Commitments and Contingencies (Details 2)           HTML     33K 
55: R68         Commitments and Contingencies (Details 3)           HTML     32K 
83: R69         Subsequent Events (Details)                         HTML     42K 
85: XML         IDEA XML File -- Filing Summary                      XML    125K 
33: EXCEL       IDEA Workbook of Financial Reports (.xls)            XLS    909K 
10: EX-101.INS  XBRL Instance -- pcrx-20121231                       XML   1.48M 
12: EX-101.CAL  XBRL Calculations -- pcrx-20121231_cal               XML    258K 
15: EX-101.DEF  XBRL Definitions -- pcrx-20121231_def                XML    769K 
13: EX-101.LAB  XBRL Labels -- pcrx-20121231_lab                     XML   3.14M 
14: EX-101.PRE  XBRL Presentations -- pcrx-20121231_pre              XML   1.39M 
11: EX-101.SCH  XBRL Schema -- pcrx-20121231                         XSD    250K 
47: ZIP         XBRL Zipped Folder -- 0001047469-13-002336-xbrl      Zip    232K 


‘EX-32.1’   —   Certification — §906 – SOA’02
Exhibit Table of Contents

Page (sequential)   (alphabetic) Top
 
11st Page  –  Filing Submission
"Exhibit 32.1
"Statement Pursuant to 18 U.S.C. S1350
"QuickLinks

This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]




QuickLinks -- Click here to rapidly navigate through this document


Exhibit 32.1

STATEMENT PURSUANT TO 18 U.S.C. §1350

        Pursuant to 18 U.S.C. §1350, the undersigned certifies that this Annual Report on Form 10-K of Pacira Pharmaceuticals, Inc. for the year ended December 31, 2012, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in this report fairly presents, in all material respects, the financial condition and results of operations of Pacira Pharmaceuticals, Inc.

Date: March 7, 2013   /s/ DAVID STACK

David Stack
President and Chief Executive Officer
(Principal Executive Officer)

 C: 


QuickLinks

STATEMENT PURSUANT TO 18 U.S.C. §1350

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
Filed on:3/7/134,  4/A,  8-K
For Period end:12/31/12ARS
 List all Filings 


2 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

12/13/13  SEC                               UPLOAD9/20/17    1:34K  Pacira BioSciences, Inc.
12/02/13  SEC                               UPLOAD9/20/17    1:153K Pacira BioSciences, Inc.
Top
Filing Submission 0001047469-13-002336   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., Mar. 29, 3:49:48.1am ET